


Claims:

1. A compound according to Formula I



(Formula I)

or a pharmaceutically acceptable salt thereof wherein

Y is a single carbon-carbon bond or a double carbon-carbon bond, with the proviso that when Y is a double carbon-carbon bond, R₁₅ and R₁₆ are not present;

one of the three positions A₁–A₃ is either S or NR_A, the remaining two positions A₁–A₃ are N or CR₁, CR₂, CR₃, respectively;

R_A is H or methyl;

R₁–R₃ are independently H, methyl, amino or halogen;

A₄–A₇ are CR₄, CR₅, CR₆ and CR₇, respectively;

A₈–A₁₂ are N or CR₈, CR₉, CR₁₀, CR₁₁ and CR₁₂, respectively, with the proviso that no more than two of the five positions A₈ – A₁₂ can be simultaneously N;

R₄ - R₇ are independently H, halogen, C(1-3)alkoxy, C(1-3)alkyl;

R₈ - R₁₂ are independently H, halogen, C(1-3)alkoxy, C(1-4)alkyl, cyano, nitro, –C(=O)OR₁₇, hydroxyl, C(3-6)cycloalkyl, benzyl, phenyl, –SF₅, bicyclo[1.1.1]pentane;

or R₉ and either R₈ or R₁₀ are fused and form an aromatic or non-aromatic five to seven membered ring containing two to seven carbon atoms and zero to three hetero atoms; with all carbon atoms optionally substituted with one or more methyl, halogen or hydroxyl;

R₁₃ is H or methyl;

R₁₄ is NH, O or S;

R'₁₅ is H, halogen, C(1-4)alkyl, -C(=O)OR₁₇ or -C(=O)NR₁₇R₁₇;

R₁₅ is H, halogen or C(1-4)alkyl;

R₁₆ is H; and,

R₁₇ is H, methyl or ethyl.

2. The compound according to claim 1, wherein A₁ is N, A₂ is NR_A and A₃ is CR₃;

~~3. The compound according to claim 2, in particular~~ wherein A₁ is N, A₂ is NH and A₃ is CH.

~~43.~~ The compound according to ~~any one of claims 1 to 3~~ or 2, wherein R₅ is C(1-3)alkoxy and R₄, R₆ and R₇ are H;

~~5. The compound according to claim 4, in particular~~ wherein R₅ is methoxy and R₄, R₆ and R₇ are H.

~~64.~~ The compound according to any one of claims 1 to ~~53~~, wherein A₈-A₁₂ are CR₈, CR₉, CR₁₀, CR₁₁ and CR₁₂ respectively;

~~7. The compound according to claim 6, in particular~~ wherein R₈-R₁₂ are independently H, C(1-4)alkyl, halogen, hydroxyl or C(1-3)alkoxy.

~~85.~~ The compound according to claim ~~74~~, wherein R₉ and R₁₁ are C(1-4)alkyl and R₈, R₁₀ and R₁₂ are H.

~~96.~~ The compound according to claim ~~85~~, wherein R₉ and R₁₁ are CF₃ and R₈, R₁₀ and R₁₂ are H.

~~107.~~ The compound according to any one of claims 1 to ~~96~~, wherein R₁₃ is H.

~~118.~~ The compound according to any one of claims 1 to ~~107~~, wherein R₁₄ is O.

~~1429~~. The compound according to any one of claims 1 to ~~1418~~, wherein R₁₅ and R'₁₅ are H.

~~14310~~. The compound according to any one of claims 1 to ~~1429~~, wherein Y is a single carbon-carbon bond.

~~14411~~. The compound according to claim 1, which is selected from the group consisting of:

4-[3-methoxy-4-(3-methylphenoxy)phenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-(2-methoxy-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)-3-(trifluoromethyl)benzonitrile;

4-[3-methoxy-4-(2-nitrophenoxy)phenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-{3-methoxy-4-[2-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-{3-methoxy-4-[4-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-{3-methoxy-4-[3-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(2-bromophenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[3-methoxy-4-(2-methylphenoxy)phenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

2-(2-methoxy-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)benzonitrile;

4-[4-(2-*tert*-butylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(2-chlorophenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-{3-methoxy-4-[2-(trifluoromethoxy)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[3-methoxy-4-(2-methoxyphenoxy)phenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(3-bromophenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(3-*tert*-butylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(3-chlorophenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-{3-methoxy-4-[3-(trifluoromethoxy)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[3-methoxy-4-(3-methoxyphenoxy)phenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

methyl 3-(2-methoxy-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)benzoate;

4-[4-(2-ethylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(3-ethylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[3-methoxy-4-(2-propylphenoxy)phenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[3-methoxy-4-[2-(propan-2-yl)phenoxy]phenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[3-methoxy-4-(2-phenylphenoxy)phenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(2-cyclopentylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(2-benzylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(2-*tert*-butyl-4-methoxyphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(2-cyclopropylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(3-*tert*-butyl-4-hydroxyphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[3-methoxy-4-[3-(propan-2-yl)phenoxy]phenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(3-cyclopropylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(2-*tert*-butyl-4-ethylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(4-bromo-2-*tert*-butylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(2-*tert*-butyl-4-methylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

methyl 3-*tert*-butyl-4-(2-methoxy-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)benzoate;

methyl 4-(2-methoxy-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)naphthalene-1-carboxylate;

4-[4-(2,4-di-*tert*-butylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[3-methoxy-4-[3-methoxy-5-(trifluoromethyl)phenoxy]phenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

3-*tert*-butyl-4-(2-methoxy-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)benzonitrile;

4-[3-methoxy-4-[2-(pentafluoro- λ^6 -sulfanyl)phenoxy]phenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

methyl 3-(2-methoxy-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)-5-(trifluoromethyl)benzoate;

4-[4-[3-bromo-5-(trifluoromethyl)phenoxy]-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(3,5-di-*tert*-butylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(2-{bicyclo[1.1.1]pentan-1-yl}phenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-(2-methoxy-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)naphthalene-1-carbonitrile;

4-[4-(2,3-dihydro-1*H*-inden-4-yloxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-{4-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)oxy]-3-methoxyphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(2,3-dihydro-1*H*-inden-5-yloxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

methyl 8-(2-methoxy-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)quinoline-5-carboxylate;

4-(3-methoxy-4-phenoxyphenyl)-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-{3-bromo-4-[3-methoxy-5-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

3-*tert*-butyl-4-(4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)benzonitrile;

4-{4-[3-methoxy-5-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

3-*tert*-butyl-4-(2-methyl-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)benzonitrile;

4-{4-[3-methoxy-5-(trifluoromethyl)phenoxy]-3-methylphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-{3-fluoro-4-[3-methoxy-5-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-{4-[2-(pentafluoro- λ^6 -sulfanyl)phenoxy]-3-(trifluoromethoxy)phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-{4-[2-(pentafluoro- λ^6 -sulfanyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[3-(trifluoromethoxy)-4-[2-(trifluoromethyl)phenoxy]phenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

3-*tert*-butyl-4-(2-methoxy-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)benzoic acid;

3-(2-methoxy-4-{6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)-5-(trifluoromethyl)benzoic acid;

4-{3-methoxy-4-[3-methyl-5-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(3,5-dimethylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-{3-methoxy-4-[2-methyl-4-(trifluoromethyl)phenoxy]phenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(2,4-dimethylphenoxy)-3-methoxyphenyl]-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(2-*tert*-butyl-4-ethylphenoxy)-3-methoxyphenyl]-2*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(2-*tert*-butyl-4-methoxyphenoxy)-3-methoxyphenyl]-2*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(2-*tert*-butyl-4-methylphenoxy)-3-methoxyphenyl]-2*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-[4-(4-bromo-2-*tert*-butylphenoxy)-3-methoxyphenyl]-2*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

4-(2-methoxy-4-{6-oxo-2*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-4-yl}phenoxy)-3-(trifluoromethyl)benzonitrile;

methyl 4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridine-

5-carboxylate;

ethyl 4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridine-

5-carboxylate;

4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-*N,N*-dimethyl-6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-

pyrazolo[3,4-*b*]pyridine-5-carboxamide;

4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-*N,N*-diethyl-6-oxo-2*H*,4*H*,5*H*,6*H*,7*H*-

pyrazolo[3,4-*b*]pyridine-5-carboxamide;

4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-1*H*,2*H*,3*H*,4*H*,6*H*-pyrrolo[3,4-*b*]pyridin-2-one;

4-{4-[3-(difluoromethyl)-5-(trifluoromethyl)phenoxy]-3-methoxyphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-

pyrazolo[3,4-*b*]pyridin-6-one;

4-{4-[2-(difluoromethyl)-4-(trifluoromethyl)phenoxy]-3-methoxyphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-

pyrazolo[3,4-*b*]pyridin-6-one;

(+)-4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-

pyrazolo[3,4-*b*]pyridin-6-one;

(-)-4-{4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl}-2*H*,4*H*,5*H*,6*H*,7*H*-pyrazolo[3,4-*b*]pyridin-6-one;

(+)-4-[4-(3,5-dimethylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;

(-)-4-[4-(3,5-dimethylphenoxy)-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;

(+)-4-{3-methoxy-4-[3-methyl-5-(trifluoromethyl)phenoxy]phenyl}-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;

(-)-4-{3-methoxy-4-[3-methyl-5-(trifluoromethyl)phenoxy]phenyl}-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one;

(+)-4-{4-[3-(difluoromethyl)-5-(trifluoromethyl)phenoxy]-3-methoxyphenyl}-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one; and,

(-)-4-{4-[3-(difluoromethyl)-5-(trifluoromethyl)phenoxy]-3-methoxyphenyl}-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one.

~~15~~12. The compound according to claim 1, which is

(+)-4-[4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one; or,

(-)-4-[4-[3,5-bis(trifluoromethyl)phenoxy]-3-methoxyphenyl]-2H,4H,5H,6H,7H-pyrazolo[3,4-b]pyridin-6-one.

~~16~~13. Medicament characterized in that it comprises a compound of Formula I according to any one of claims 1 to ~~15~~12 or a pharmaceutically acceptable salt thereof.

~~17~~14. Compound according to any one of claims 1 to ~~15~~12 or a pharmaceutically acceptable salt thereof for use in therapy.

~~18~~15. ~~Compound~~Use of a compound according to any one of claims 1 to ~~15~~12 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the therapeutic and / or prophylactic treatment of ERR α -mediated diseases or conditions.

~~19~~16. ~~Compound~~Use of a compound according to any one of claims 1 to ~~15~~12 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of ERR α -mediated cancer.

~~2017. Compound~~Use of a compound according to any one of claims 1 to ~~15~~12 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of at least one condition selected from: lung cancer; melanoma; endometrial cancer; and, acute myeloid leukemia.

~~2118. Compound~~Use of a compound according to any one of claims 1 to ~~15~~12 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of at least one condition selected from: breast cancer; bladder cancer; prostate cancer; pancreatic cancer; colorectal cancer; and, ovarian cancer.

~~2219. Compound~~Use of a compound according to any one of claims 1 to ~~15~~12 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of Type II diabetes mellitus.

~~2320. Pharmaceutical composition~~ which comprises a compound of Formula I according to any one of claims 1 to ~~15~~12 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

~~24. Pharmaceutical composition according to claim 23, in particular which pharmaceutical composition~~ further comprises at least one additional therapeutically active agent.